Using Mölkky for Community-dwelling Older Adults
NCT07025967, Not applicable, Completed, The Hong Kong Polytechnic University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Using Mölkky for Community-dwelling Older Adults | ClinicalTrials.gov |
| NCT number | NCT07025967 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 50 participants, actual | ClinicalTrials.gov |
| Lead sponsor | The Hong Kong Polytechnic University | ClinicalTrials.gov |
| Conditions | Older Adults Without Any Specific Clinical Condition | ClinicalTrials.gov |
| Interventions | Mölkky, Home activity | ClinicalTrials.gov |
| First posted | 2025-06-18 | ClinicalTrials.gov |
| Last updated | 2026-09-16 | ClinicalTrials.gov |
Registered outcomes 7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Chinese Stroop Color and Word Test (Stroop) | Before the intervention to the end of intervention at 8 weeks; 6 months after the intervention | The Chinese Stroop is used to assess participants' selective attention and cognitive flexibility. There are three sub-tests in the Stroop, identifying color of dots (Stroop I), identifying the words under incongruent conditions (Stroop II) and identifying the color of words under incongruent conditions (Stroop III). The time spent on each sub-test and errors which are not self-corrected are recorded. Time interference score is calculated by the formula: Interference = Stroop III - \[(Stroop I + Stroop II) / 2\], a lower time interference score indicates better performance. The Chinese Stroop has good reliability and validity. | ClinicalTrials.gov |
| Secondary | Hong Kong version of Montreal Cognitive Assessment (HK-MoCA) | Before the intervention to the end of intervention at 8 weeks; 6 months after the intervention | The HK-MoCA is used to assess participants' overall cognitive ability including visuospatial function, naming, delayed recall, attention, language, abstraction, and orientation. A higher score out of 30 indicates better cognition. The HK-MoCA is a reliable and valid cognitive assessment. | ClinicalTrials.gov |
| Secondary | Two-Minute Step Test (TMST) | Before the intervention to the end of intervention at 8 weeks; 6 months after the intervention | The TMST is used to assess participants' lower limb muscle strength, endurance, and cardiorespiratory endurance. Participants are asked to repeat the action of stepping alternatively in two minutes, the total number of times the right knee is lifted is recorded. Post-it notes placed on the wall next to the participants are used as a height marker for each step, the greater the number of steps that meet the marker, the better the participants' cardiovascular fitness. The TMST is a reliable and valid assessment tool. | ClinicalTrials.gov |
| Secondary | Timed Up and Go Test (TUG) | Before the intervention to the end of intervention at 8 weeks; 6 months after the intervention | The TUG is used to assess participants' functional mobility. Participants are asked to stand up from a chair, walk 3 meters, turn around and go back to their seat. Time used is recorded, a shorter time indicates better physical functioning. The TUG is both reliable and valid assessment. | ClinicalTrials.gov |
| Secondary | Geriatric Depression Scale Cantonese Version (GDS-C) | Before the intervention to the end of intervention at 8 weeks; 6 months after the intervention | The GDS-C is used to assess participants' psychological well-being. Participants will answer 15 yes-no questions regarding their perception and attitude of their daily lives. A score of 8 or above indicates depressive symptoms. The GDS-C is reliable and valid. | ClinicalTrials.gov |
| Secondary | EuroQol-five Dimensions Questionnaire - Hong Kong Chinese version (EQ-5D-5L) | Before the intervention to the end of intervention at 8 weeks; 6 months after the intervention | The EQ-5D-5L is used to assess health-related QoL. Participants will rate their health states from 1 to 5 (1 indicates no problem and 5 indicates extreme problems/unable to perform) based on the severity of their problems in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5-levels of health states are converted to a utility value using a local value. The EQ-5D-5L is reliable and valid. | ClinicalTrials.gov |
| Other | Physical Activity Enjoyment Scale (PAES) | Before the intervention to the end of intervention at 8 weeks | The PAES is used to assess participants' attitudes towards physical activity. Participants will rate eight bipolar items by the scale of 1 to 7 on enjoyment, emotion, and engagement level. The negative items (Items 1, 4, 5 and 7) are reverse coded, meaning that score of 1 will be changed to 7, 2 changed to 6, 3 changed to 5 and vice versa. A score of 4 will remain unchanged for these negative items. The sum of scores of items is calculated. A higher PAES score indicates a greater level of enjoyment in physical activity. The PAES is reliable and valid. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)